A Phase I Dose Escalation Study of Intermittent Oral OSI-906 Dosing in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 10 Sep 2014
At a glance
- Drugs Linsitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Astellas Pharma
- 03 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Nov 2010 Planned End Date changed from 1 Nov 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 26 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.